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Abstract 
Saccadic eye movements are controlled by a network of parietal, frontal, striatal and cerebellar 
regions. The saccadic peak velocity is an established biomarker of benzodiazepine effects, with 
benzodiazepines reliably reducing the peak velocity. Here, we explored the roles of sex, intelligence, 
age and task characteristics in this effect and investigated benzodiazepine effects on previously less 
studied measures of saccades in a double-blind, within-subjects design. Healthy adults (N=34) 
performed a horizontal step prosaccade task under 1mg lorazepam, 2mg lorazepam and placebo. We 
replicated the dose-dependent reduction in peak velocity with lorazepam and showed that this effect 
was stronger for saccades to targets at smaller eccentricities. We also demonstrated that this effect 
is independent of sex and other trait variables. Lorazepam effects were widespread, however, 
occurring on mean and variability measures of most saccadic variables. Additionally, there were sex-
dependent lorazepam effects on spatial consistency of saccades, indicating more adverse effects in 
females. We conclude that saccadic peak velocity is a sensitive and robust biomarker of 
benzodiazepine effects, but that lorazepam has pronounced effects also on other parameters of 
horizontal saccades. Sex-dependent drug effects on spatial consistency may reflect cerebellar 
mechanisms, given the role of the cerebellum in saccadic spatial accuracy. 
 
Keywords 
Lorazepam, benzodiazepine, saccadic eye movements, oculography, biomarker, sex differences, 
anxiety 
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Introduction 
The peak velocity of saccadic eye movements is an established biomarker of GABAergic 
benzodiazepine effects (Atack, 2008; Chen et al., 2012; De Visser et al., 2003). However, despite the 
widespread use of this measure in drug studies, there are a number of gaps in our knowledge of 
benzodiazepine effects on saccadic peak velocity. These concern primarily the role of participant 
baseline variables that may explain variance in benzodiazepine effects, such as sex, age, anxiety or 
intelligence; the effects of benzodiazepines on intra-individual variability; and the role of 
experimental task factors in these effects. Additionally, whilst saccadic peak velocity is frequently 
studied, there are other saccadic measures whose modulation by benzodiazepines has not yet been 
investigated. To address these questions, we carried out a comprehensive examination of the effects 
of lorazepam on peak velocity and other saccadic variables. Our aims were as follows. 
 
First, we aimed to replicate the previously reported reduction of peak velocity by benzodiazepines 
(De Visser et al., 2003) using a horizontal, centrifugal, step saccade paradigm. We chose lorazepam as 
it is a widely prescribed drug and a frequently used comparator compound in the examination of 
novel compounds (e.g., Atack, 2008; de Haas et al., 2009). We applied multiple doses of lorazepam 
(1mg, 2mg) in order to assess the dose-dependency of any effects. 
 
Second, we aimed to investigate the role of sex1 in the effects of lorazepam. Sex is a primary domain 
of variation in biomedical research (Brooks and Clayton, 2017; Tannenbaum et al., 2016). However, 
much preclinical and clinical research includes only male humans or animals or fails to identify the 
subjects’ sex (Brooks and Clayton, 2017). Studying sex differences is particularly relevant in the 
investigation of treatments for disorders that differ in their prevalence between males and females. 
Specifically, whilst females have an approximately two-fold higher risk for anxiety disorders than 
males (Kessler et al., 2011; Tolin and Foa, 2006), not enough is known about the role of sex in the 
pharmacological treatment of these disorders (Bekker and van Mens-Verhulst, 2007). Similarly, most 
previous studies of benzodiazepine effects on saccades were performed in males, and no study, to 
our knowledge, has considered the role of sex in the reported effects. 
 
                                                          
1
 In this study, we use the term “sex” to denote biological sex, as indicated by participants’ self-report. We 
acknowledge that in humans the term biological “sex” is confounded with, and difficult to separate from, the 
more psychosocial concept “gender” (Brooks and Clayton, 2017). 
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Third, we explored the role of other relevant baseline variables along which individuals differ and 
which may relate to lorazepam effects, such as age, trait anxiety and intelligence. Inter-individual 
variation contributes significantly towards the heterogeneity of brain structure and function (Brooks 
and Clayton, 2017) and the ability to predict treatment response using such baseline measures 
remains a formidable challenge (Owen et al., 2013). The roles of age, trait anxiety and intelligence 
have, to our knowledge, not been considered in benzodiazepine effects on saccades. 
 
Fourth, we aimed to characterise lorazepam effects on other saccadic variables, in addition to peak 
velocity. Whilst peak velocity is a well-established biomarker of benzodiazepine effects (De Visser et 
al., 2003), saccadic tasks yield a rich array of performance measures (Holmqvist et al., 2011; Leigh 
and Zee, 2015). The widespread expression of GABAA receptors in brain (Uusi-Oukari and Korpi, 
2010), especially the α1 subunit thought to be responsible for the sedative effects of 
benzodiazepines (Chen et al., 2012), suggests that lorazepam influences likely manifest themselves 
throughout the neural network underlying saccades (Leigh and Zee, 2015), thereby affecting diverse 
performance measures. 
 
For example, detailed analysis of the temporal waveform of saccades yields measures of average 
velocity, Q and skewness. Average velocity is calculated as the ratio of amplitude and duration and 
has been found to be reduced by lorazepam (Harron et al., 1995). Q refers to the ratio of peak and 
average velocity (Leigh and Zee, 2015). Benzodiazepine effects on Q have, to our knowledge, not 
been investigated. This is important, as a reduction in Q would be indicative of a more pronounced 
effect on peak than average velocity, buttressing the primacy of peak velocity as a benzodiazepine 
biomarker. Skewness refers to the ratio between time to reach peak velocity (acceleration phase) 
and the total saccade duration (combining acceleration and deceleration phases) (Collewijn et al., 
1988). Benzodiazepine effects on skewness have, to our knowledge, not been reported. Whilst two 
previous studies observed a reduction in acceleration/deceleration ratio with midazolam (Ball et al., 
1991) and lorazepam (King et al., 1995), another study observed increased acceleration phase with 
diazepam (Roy-Byrne, Cowley, Radant, Hommer, & Greenblatt, 1993). However, these measures 
differ from skewness, as they do not take into account saccade duration (Leigh and Zee, 2015). 
 
Another measure that has not been investigated in relation to benzodiazepine effects is saccadic 
curvature. The trajectories of horizontal saccades are rarely entirely straight but typically show some 
degree of curvature (Smit and Van Gisbergen, 1990; Yarbus, 1967). Curvature is influenced by 
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attentional factors (Sheliga et al., 1994) and is related to neuronal activity in frontal eye fields and 
superior colliculus (Port and Wurtz, 2003), suggesting that exogenous GABAergic modulation of these 
neurons may affect this metric. However, to our knowledge, no previous study has investigated 
benzodiazepine influences on saccadic curvature in humans. 
 
We also investigated saccade latency and measures of spatial accuracy. Latency reflects the speed of 
visual information processing, decision making and response execution processed in subcortical and 
cortical areas (Carpenter, 2004). Spatial accuracy is a function of sensorimotor transformations which 
involve dorsal stream cortical areas, but is also sensitive to cerebellar integrity (Robinson & Fuchs, 
2001). Previous studies have found lorazepam to increase latency (Chen et al., 2014, 2015; de Haas 
et al., 2009; de Haas et al., 2007, 2008; Green, King, & Trimble, 2000; Masson et al., 2000; Tedeschi, 
Smith, Dhillon, & Richens, 1983) and reduce spatial accuracy (Chen et al., 2014, 2015; de Haas et al., 
2009; de Haas et al., 2007, 2008; King et al., 1995; Masson et al., 2000). 
 
Fifth, we wished to assess lorazepam effects not merely on mean performance measures, but also on 
intra-individual variability of performance. Intra-individual variability is an important phenomenon in 
studies of drug effects (Coghill et al., 2014) and psychopathology (Kuntsi and Klein, 2011). While one 
previous study showed that 1mg lorazepam increases the variance in saccadic latency (Masson et al., 
2000), it is unknown whether lorazepam systematically affects intra-individual variability across 
saccadic measures. 
 
A sixth aim was whether the internal consistency of performance is affected by lorazepam. Reduced 
internal consistency of a measure, e.g. Cronbach’s alpha, would be indicative of less consistent 
responding, possibly due to increased intra-individual variability. 
 
Seventh, a final aim was to investigate the role of task factors such as stimulus direction (right, left) 
and distance (near, far), and their role in lorazepam effects. Task factors, especially stimulus distance 
from centre, are known to affect saccadic performance (Leigh and Zee, 2015) but have not, to our 
knowledge, been investigated in relation to benzodiazepines. 
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On the basis of above literature, our hypotheses were that lorazepam would have adverse effects on 
peak and average velocity, latency and duration. Further, as stated earlier, we aimed to characterise 
lorazepam effects on mean and variability measures not previously considered and explore the roles 
of sex, age, trait anxiety, intelligence and task-related factors in lorazepam effects. 
 
Method 
Participants 
Healthy volunteers were recruited via circular emails to staff and students of King’s College London, 
UK. Participants underwent a thorough physical and psychiatric assessment by the study doctor 
before admission to the study to ensure they were in good physical and mental health. All 
participants had normal or corrected-to-normal vision. 
 
The study was approved by King’s College Hospital Research Ethics Committee. Participants gave 
written informed consent before participating. 
 
Design and Procedure 
The study employed a double-blind, placebo-controlled, within-subjects design with order of drug 
administration randomised. Each participant was assessed three times, under placebo (50mg 
ascorbic acid), 1mg lorazepam and 2mg lorazepam. Sessions were separated by at least a week to 
allow for adequate drug washout. Assessments took place in the afternoon, between 1.30pm and 
6.30pm, with the time of assessment kept the same for each participant as closely as possible. 
 
On study days, participants’ current health was first verified by study staff. A capsule containing the 
drug or placebo was then administered p.o. with 300ml of water. After a 120 minutes wait for the 
drug to reach peak concentrations in blood (Kyriakopoulos et al., 1978), participants completed 
cognitive tasks (Perkins et al., 2013a, 2013b) lasting approximately 40 minutes, followed by the 
saccade task. 
 
Saccade Task 
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The saccade task was written using ExperimentBuilder (SR Research Ltd., Ontario, Canada). 
Participants were seated with their eyes 57cm from a 19-in monitor (visible screen area 360mm x 
270mm, 1024 x 768 pixels, 60 Hz refresh rate), with the head on a chinrest. They were shown a 
stimulus on the monitor and were asked to follow it with their eyes as fast and accurately as possible 
without moving the head. The stimulus was a black circle (0.3°), presented on white background. 
Before each trial, a drift correction procedure was carried out. A trial began with the stimulus shown 
in the central position of the monitor for a random duration of 500-1500ms, before it stepped to one 
of four horizontal positions (right far (RF): +14.5°, right near (RN): +7.25°, left near (LN): -7.25°, left 
far (LF): -14.5°), where it remained for 1000ms. Each peripheral location was used 15 times in a 
random order, resulting in a total of 60 trials. Four practice trials were carried out before the task. 
 
Movements of the right eye were recorded using a video-based corneal reflection and pupil tracker 
(Eyelink 1000, SR Research Ltd.) at 1000 Hz sampling rate. A 9-point calibration was carried out 
before the beginning of the task. 
 
Saccade data were processed blind to drug group using EyeLink DataViewer (SR Research Ltd.) and 
Matlab (The Mathworks, Natick, MA, USA). For each trial, the first saccade following onset of the 
peripheral stimulus was included in analysis if (i) it was made in the direction of the peripheral 
stimulus, (ii) it had a minimum amplitude of 1°, (iii) it had a minimum latency to stimulus of 70ms, (iv) 
there was no blink or saccade in the window from 100ms before to onset of peripheral stimulus, (v) 
there was no blink within the saccade, and (vi) the saccade start position did not deviate from the 
central stimulus position by more than 50 pixels horizontally or vertically. 
 
The following dependent variables were extracted for included saccades at each peripheral stimulus 
position (±7.25°, ±14.5°). 
 Latency: the time from peripheral stimulus onset to saccade onset (ms). 
 Amplitude gain: the ratio of saccade amplitude divided by desired amplitude. A saccade with 
perfect spatial accuracy thus has a score of 1. Smaller scores indicate hypometric 
(undershooting) saccades and larger scores indicate hypermetric (overshooting) saccades. 
 Spatial error: the residual position error. This measure was obtained by subtracting the 
desired saccade amplitude (±7.25° or ±14.5°, depending on peripheral stimulus location) 
from the actual saccade amplitude and dividing the result by the desired saccade amplitude. 
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The absolute value of this term reflects the residual error; this was then averaged across all 
saccades. A saccade with perfect spatial accuracy thus has a score of 0, and higher scores 
indicate greater spatial error, irrespective of saccadic overshoot or undershoot. 
 Peak velocity: the maximal velocity of the saccade (°/sec). 
 Average velocity: the mean velocity of the saccade (°/sec). 
 Duration: the time from saccade onset to offset (ms). 
 Curvature:  the maximal deviation of vertical eye position during a saccade adjusted for the 
final vertical eye position in the saccade. This measure is calculated by subtracting the final 
eye position in the saccade from the maximal deviation of eye position during the saccade. 
 Skewness: the ratio of acceleration and deceleration phases. This measure is calculated as 
the time (ms) from saccade onset to peak velocity divided by the time (ms) from peak 
velocity to saccade offset. A perfectly symmetrical saccadic waveform thus has a score of .5. 
Smaller scores indicate a shorter acceleration than deceleration phase, and larger scores 
indicate a shorter deceleration than acceleration phase. 
 Q: the relationship between peak velocity and average velocity. This measure is calculated by 
dividing the peak velocity by the average velocity. 
 
For each variable, each participant’s mean score was calculated. Additionally, for latency, amplitude 
gain, peak and average velocity, duration as well as curvature, the intra-individual coefficient of 
variation (ICV) was calculated as a measure of variability by dividing a participant’s intra-individual 
standard deviation by his/her mean score. Only participants who had at least 5 correct trials at each 
peripheral stimulus position were included in statistical analysis. 
 
Psychometric Assessment 
Age and sex were measured using a self-report questionnaire. 
 
Trait anxiety was measured using the State Trait Anxiety Inventory (STAI) (Spielberger et al., 1983). 
This 20-item questionnaire is a well-established measure of trait anxiety. Higher scores indicate 
higher levels of anxiety. 
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Intelligence was estimated using the 16PF reasoning ability scale (Cattell et al., 1970). This 13-item 
test is a validated short scale measure of intelligence (Abel and Brown, 1998). The possible score 
range is 0-13, with higher scores indicating better performance. 
 
Statistical Analysis 
Statistical analysis was carried out using SPSS 22.0 (IBM, Armonk, NY, USA) unless otherwise noted. 
 
To assess effects of lorazepam, mixed-model analyse of variance (ANOVA) were carried out for each 
dependent variable with the within-subjects factors Drug (placebo, 1mg lorazepam, 2mg lorazepam), 
Direction (right, left) and Distance (near, far) and the between-subjects factor Sex (male, female). 
Significant interactions were followed up with t-tests using Bonferroni correction of the alpha level. 
 
To assess the role of demographic variables in lorazepam effects, change scores (placebo – drug) 
were calculated for each variable, separately for 1mg and 2mg doses. These change scores were 
correlated with age, STAI trait anxiety and 16PF reasoning score, using Bonferroni correction of the 
alpha level (0.05 / 128 = 0.0004). 
 
To assess internal consistency, Cronbach’s alpha was calculated over the individual trials for each 
variable in each Drug condition (1mg, 2mg, placebo), independent of Direction and Distance. To 
assess effects of lorazepam on internal consistency, Cronbach’s alphas were compared across Drug 
conditions using the Cran R package cocron (Diedenhofen and Musch, 2016). 
 
Results 
Descriptive Statistics 
A total of N=40 participants completed the study. Six participants were excluded from analyses as 
they did not meet the minimum number criterion of 5 trials per peripheral stimulus position, leaving 
a final sample of N=34 (Table 1). 
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Spatial error, Q, curvature and the ICVs of gain, peak velocity, duration, latency and curvature were 
positively skewed and, therefore, log-transformed. Descriptive statistics of all variables are in Table 2 
(males) and Table 3 (females). ANOVA results are in Table 4. 
 
=== INSERT TABLES ABOUT HERE === 
 
Drug and Task Effects on Performance 
There were significant main effects of Drug on all variables, with the exception of duration (p=0.87), 
curvature (p=0.82) and ICV of spatial error (p=0.55). These results indicate negative effects of 
lorazepam: increased latency, reduced amplitude gain, increased spatial error, reduced peak velocity, 
reduced average velocity, increased skewness, reduced Q and increased ICV of latency, amplitude 
gain, peak velocity, average velocity, duration and curvature. 
 
For explanatory purposes, increased skewness scores due to lorazepam reflect a relative increase in 
acceleration time and a relative decrease in deceleration time. Reduced Q due to lorazepam 
indicates a reduction in the ratio between peak and average velocity, suggesting that the reduction in 
peak velocity due to lorazepam was more pronounced than the reduction in average velocity. 
 
Effects on velocity and duration have to be interpreted by considering the known relationships of 
these variables with saccadic amplitude (Bahill et al., 1975; Westheimer, 1954), given that lorazepam 
caused reduced saccadic amplitudes in our data. Therefore, we calculated the ratios of both peak 
and average velocity as well as duration over saccade amplitude (Sweeney et al., 1997). For the 
amplitude-corrected measure of peak velocity (log transformed due to positive skew), there was a 
main effect of Drug (F[2,64]=7.46, p=0.001, ηp²=0.19), confirming above finding. However, there was 
no main effect of Drug on amplitude-corrected average velocity (F[2,64]=0.93, p=0.40, ηp²=0.03). For 
amplitude-corrected duration, a main effect of Drug emerged (F[2,64]=18.36, p<0.001, ηp²=0.37), 
suggesting that lorazepam increased saccade duration when correcting for amplitude. 
 
Simple contrasts to follow up main effects of Drug revealed that all pairwise differences between 
placebo, 1mg and 2mg lorazepam were significant (all p<0.05), with the exceptions of the contrast 
placebo vs. 1mg for latency (p=0.50), skewness (p=0.29), latency ICV (p=0.08), duration ICV (p=0.09), 
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curvature ICV (p=0.30) and the contrast 1mg vs. 2mg for amplitude-corrected peak velocity (p=0.34), 
Q (p=0.40) and latency ICV (p=0.19). 
 
Main effects of Sex showed that males had greater spatial error, higher skewness and greater ICV of 
gain than females. For explanatory purposes, higher skewness in males indicates that the onset of 
peak velocity in the saccade occurred later than in females. 
 
Drug by Sex interactions were observed for spatial error and ICV of gain, indicating stronger negative 
responses to lorazepam in females than males on both variables (Figure 1). The comparison of 2mg 
vs. placebo was significant in both males and females for both variables (p<0.003), but the 
comparison of 2mg vs. 1mg was significant only in females for both variables (p<0.001) but not in 
males for either variable (p>0.12). The effect of 1mg vs. placebo was significant in females for both 
variables (p≤0.005) but not in males for either variable (p>0.05). Males had higher spatial error and 
ICV of gain than females only on placebo (both p≤0.001), but not on lorazepam (all p>0.007, not 
surviving Bonferroni corrected alpha level of p=0.0056). 
 
Drug by Distance interactions were observed for gain, peak velocity and Q. For amplitude-corrected 
average velocity, a Drug by Distance interaction emerged (F[2,64]=4.38, p=0.02, ηp²=0.12). Similarly, 
a Drug by Distance interaction emerged for amplitude-corrected duration (F[2,64]=3.35, p=0.04, 
ηp²=0.10). 
 
For gain, the interaction indicated stronger reductions with lorazepam for near (all p<0.004) than far 
stimuli, and only the comparison of 2mg vs. placebo reached Bonferroni corrected significance 
(p<0.001; all other p>0.009 and n.s. at corrected alpha level p=0.0056). Effects of Distance were 
observed for placebo (p<0.001) and 1mg (p=0.004), but not 2mg (p=0.86). 
 
For peak velocity, the interaction similarly indicated that reductions due to lorazepam were more 
pronounced for near than far stimuli, with all pairwise comparisons significant for near stimuli (all 
p≤0.001), whereas for far stimuli the comparison of 1mg vs. 2mg was not significant (p=0.11; all 
other p<0.001). Effects of Distance were significant for all Drug conditions (all p<0.001) (Figure 2). 
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For Q, the interaction suggested a stronger reduction with lorazepam for near than far stimuli. 
Pairwise comparisons were significant for near stimuli at 2mg vs. placebo (p=0.001) and 1mg vs. 
placebo (but not surviving Bonferroni corrected alpha level of p=0.0056; p=0.02) but not 1mg vs. 2mg 
(p=0.07). For far stimuli only the comparison of 2mg vs. placebo was significant (p=0.001; other 
p>0.05). Effects of Distance were observed for placebo and 1mg (both p<0.001), but not 2mg 
(p=0.01; not surviving Bonferroni corrected alpha level of p=0.0056). 
 
For amplitude-corrected average velocity, the interaction indicated that reductions due to lorazepam 
occurred for near (1mg vs. placebo, p=0.04, not surviving Bonferroni corrected alpha level of 
p=0.0056) but not far stimuli (all p>0.58). Effects of Distance were significant for all Drug conditions 
(all p<0.001). 
 
For amplitude-corrected duration, effects of Drug were observed at both near and far stimuli (all 
p<0.001) with the exception of 1mg vs. placebo (both p>0.04, not surviving Bonferroni corrected 
alpha level of p=0.0056). Effects of Distance were significant for all Drug conditions (all p<0.001). 
 
Drug by Direction interactions were observed for average velocity, skewness and Q. For amplitude-
corrected average velocity, the interaction became non-significant (p=0.09). For amplitude-corrected 
duration, an interaction arose (F[2,64]=3.20, p=0.047, ηp²=0.09). 
 
For average velocity, the interaction indicated stronger reductions with lorazepam for saccades to 
the right (all p<0.002) than the left (all p>0.01; not significant at Bonferroni corrected alpha level of 
0.0056). Effects of Direction were significant for placebo (p<0.001), but not lorazepam conditions 
(p>0.02). 
 
For skewness, the interaction indicated stronger increases with lorazepam for saccades to the left 
(p<0.001 for 2mg vs. placebo; other p>0.007, n.s. at Bonferroni corrected alpha level of p=0.0056) 
than to the right (all p>0.22). There were no significant effects of Direction at each level of Drug (all 
p>0.01, n.s.). 
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For Q, the interaction suggested stronger reductions with lorazepam for saccades to the left (p<0.001 
for 1mg vs. placebo and for 2mg vs. placebo; other p=0.19) than to the right (all p>0.13). There was a 
significant effect of Direction only for 2mg (p=0.003; other p>0.01, n.s. at Bonferroni corrected alpha 
level of p=0.0056). 
 
For amplitude-corrected duration, the interaction indicated stronger increases with lorazepam for 
saccades to the right (all p<0.002) than the left (1mg vs. placebo: p=0.60; 1mg vs. 2mg: p=0.002; 2mg 
vs. placebo: p=0.004). Effects of Direction were significant for placebo (p<0.001), but not lorazepam 
conditions (p>0.03). 
 
Finally, there were a number of main effects and interactions involving Direction, Distance and Sex, 
but not Drug. 
 
Main effects of Distance indicated that saccades to near stimuli had higher gain, lower average and 
peak velocity (also amplitude-corrected), shorter duration (also amplitude-corrected), shorter 
latency, higher skewness, higher Q, higher curvature and higher ICVs of gain, spatial error and peak 
velocity than saccades to far stimuli. 
 
Main effects of Direction indicated that saccades to stimuli in the right hemifield had lower spatial 
error, higher average and peak velocity (also amplitude-corrected), shorter duration (also amplitude-
corrected), and higher Q than saccades to stimuli in the left hemifield. 
 
Direction by Sex interactions were observed for peak velocity, skewness and curvature. For 
amplitude-corrected peak velocity, however, the interaction was non-significant (p=0.26). 
 
For peak velocity, the interaction indicated higher peak velocity for right than left saccades for males 
(p<0.001) but not females (p=0.10). Sex differences were not significant for either direction (both 
p>0.25). 
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For skewness, the interaction indicated greater skewness for left than right saccades for males 
(p=0.001) but not females (p=0.63). Sex differences were observed for saccades to the left (p=0.001) 
but not to the right (p=0.08). 
 
For curvature, there were no significant post-hoc tests (all p>0.30). 
 
A Distance by Sex interaction was observed for average velocity ICV, indicating that the effects of 
Distance was stronger for females (p=0.02; but not surviving Bonferroni corrected alpha level of 
0.0125) than for males (p=0.15). Males had greater ICV than females for far (p=0.03; not surviving 
Bonferroni corrected level of 0.0125) but not for near (p=0.52) stimuli. 
 
A Direction by Distance interaction for skewness indicated that greater skewness for saccades to the 
left than to the right was observed for far (p=0.002) but not near (p=0.75) stimuli. Effects of Distance 
were observed for saccades both to the right and to the left (both p≤0.001). 
 
Drug Effects on Internal Consistency 
Cronbach’s alphas were high for most saccade variables (ranging from 0.75 to 0.94), with the 
exception of somewhat lower alphas for curvature (ranging from 0.59 to 0.73) (Table 5). There were 
no significant differences between the Drug conditions in internal consistency of any variables (all 
p>0.02, n.s. at Bonferroni corrected alpha level of 0.0167). 
 
Correlations of Psychometric Variables with Change Scores 
There were no significant correlations of age, nonverbal intelligence and trait anxiety with change 
scores from placebo for performance under either 1mg or 2mg lorazepam (all r<0.49, all p>0.003, n.s. 
at Bonferroni corrected alpha level of 0.0003) (see Supplementary Table 1). 
 
Discussion 
The key findings from this study are as follows. First, we confirmed that lorazepam reduces saccadic 
peak velocity and we demonstrated that this effect is both sensitive to dose and independent of age, 
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sex, trait anxiety and intelligence. The sensitivity of peak velocity was further underscored by the 
effect of lorazepam on Q, a measure of the ratio between peak and average velocity, showing that 
the drug effect was more pronounced on peak than average velocity. Second, lorazepam effects on 
saccades were widespread, with deteriorations observed on most mean and variability measures. 
Notably, however, the internal reliability of performance (Cronbach’s alpha) was not affected. Third, 
lorazepam effects interacted with sex on consistency measures of spatial accuracy, indicating more 
pronounced adverse effects in females. Fourth, there was evidence that lorazepam effects depend 
on task factors. Effects on peak velocity, gain and Q were more pronounced for near than far stimuli. 
Effects on average velocity were more pronounced for saccades to the right, whereas effects on 
skewness and Q were stronger for saccades to the left. Fifth, analysis of dose-dependency showed 
that most variables were sensitive to both 1mg lorazepam compared to placebo and an increase 
from 1mg to 2mg. Exceptions were latency, skewness, and the variabilities of latency, duration and 
curvature, which showed deterioration from placebo only with 2mg, suggesting these measures are 
less suited to detecting low-dose lorazepam effects. 
 
Lorazepam Effects 
Using a multi-dose, within-subjects design, we replicated the well-established finding of reduced 
saccadic peak velocity following benzodiazepine administration. Considering the magnitude of the 
effect observed in this study and the consistency of this finding across numerous studies using 
various benzodiazepine compounds (De Visser et al., 2003), we argue that this effect is likely to be 
one of the most consistent findings in cognitive psychopharmacology. 
 
The current study advances this literature in a number of ways. First, we confirmed that the effect on 
peak velocity is independent of sex, age, trait anxiety and intelligence. The reason for investigating 
these possible predictor variables lies in the known variability in pharmacological response across 
individuals and the importance of developing individualised treatment strategies, e.g. by taking into 
account patients’ baseline measurements (Owen et al., 2013). We can thus conclude that the effect 
of lorazepam on saccadic peak velocity is fundamental, i.e. independent of the participant variables 
studied here, at least within the range of scores observed in this carefully selected, healthy sample. 
 
Second, we extend previous studies by demonstrating that lorazepam effects on saccades are 
pronounced, affecting all measured aspects of performance. Most previous studies have focussed on 
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peak velocity, and no previous study has investigated a spectrum of variables as comprehensive as 
that reported here. Therefore, and because our study included multiple doses and a larger sample 
than most other studies in the field (De Visser et al., 2003), our findings provide an important archive 
of lorazepam effects across saccadic performance measures. To summarise, lorazepam led to 
increased latency, reduced spatial accuracy, reduced average velocity, reduced peak/average velocity 
ratio (Q), increased skewness, increased curvature, and increased intra-individual variabilities of all 
measures except spatial error. Most variables showed evidence of dose-dependency, except mean 
latency, mean skewness, latency variability, duration variability and curvature variability for the 
comparison of placebo vs. 1mg, as well as Q, amplitude-corrected peak velocity and latency 
variability for the comparison of 1mg vs. 2mg. 
 
Taken together, and comparing these data to the often much more subtle and specific effects of 
other substances on oculomotor measures (Ettinger and Kumari, 2003; Reilly et al., 2008), the picture 
that emerges is that benzodiazepines cause a fundamental, nonspecific destabilisation of the neural 
system controlling saccadic eye movements. The macroscopic neural mechanisms underlying this 
effects remain unknown, necessitating functional neuroimaging studies (Minzenberg, 2012; Nathan 
et al., 2014). The distribution of GABAA receptors in brain and the observed pattern of lorazepam 
effects suggest that various structures in the neural network underlying saccades are affected, from 
cortical eye fields to brainstem. 
 
Specifically, peak velocity is related to activity of burst neurons in the pontine reticular formation 
(Fuchs et al., 1985), suggesting that the robust reduction of peak velocity in this and other studies is a 
result of GABAergic effects on brainstem neurons. Saccadic latency, on the other hand, is a 
composite measure that reflects perceptual processes, attention, target selection, decision making 
and programming premotor commands and is subject to both top-down and bottom-up influences 
(Carpenter, 2004; Hutton, 2008). Benzodiazepine effects on saccadic latency have been observed 
previously (Chen et al., 2014, 2015; de Haas et al., 2009; de Haas et al., 2007, 2008; Green et al., 
2000; Masson et al., 2000; Tedeschi et al., 1983). The increase in latency could reflect a delay in the 
programming of the saccadic command (Masson et al., 2000) and may stem from GABAergic effects 
in frontal or parietal eye fields (Roy-Byrne et al., 1993; Sommer and Tehovnik, 1997). Reduced spatial 
accuracy following benzodiazepines has also been observed previously (Chen et al., 2014, 2015; de 
Haas et al., 2007, 2008, 2009; King et al., 1995; Masson et al., 2000), and might reflect lorazepam’s 
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action in frontal eye fields or cerebellum (Glue, 1991; Robinson & Fuchs, 2001; Sommer & Tehovnik, 
1997). Effects on curvature may arise in the brainstem (Leigh and Zee, 2015). 
 
Some lorazepam effects interacted with task variables. Specifically, effects on gain, peak velocity and 
Q were more pronounced for near than far stimuli. Effects on average velocity were more 
pronounced for saccades to the right, whereas effects on skewness and Q were stronger for saccades 
to the left. An important implication of these findings for future drug screening studies using saccadic 
biomarkers is to include multiple stimulus positions, in order to be able to detect adverse drug 
effects with maximal sensitivity, especially for comparisons between different drug doses. 
 
Finally, an interesting observation of this study was that the internal reliability (Cronbach’s alpha) of 
performance was not significantly altered by lorazepam. This finding suggests that despite the 
observed increases in intra-individual variability of some measures, performance remained 
consistent across individuals. An important corollary of this finding is that lorazepam does not reduce 
the internal reliability with which saccadic performance is measured, even at a dose of 2mg. 
 
Sex-Dependent Effects of Lorazepam 
In addition to these main effects of lorazepam, there was evidence of sex-dependent effects on two 
saccadic measures, viz. the intra-individual variability of spatial error and amplitude gain. These 
findings indicated that adverse effects of lorazepam on these variables were stronger in females than 
in males. The spatial accuracy of saccades reflects basic sensorimotor transformation processes that 
rely on cerebellar integrity (Ettinger et al., 2005; Robinson & Fuchs, 2001). 
 
The current finding of sex-dependent lorazepam effects on spatial accuracy may thus be explained 
via the drug’s action in the cerebellum and sex differences in mediating these effects. Support for 
this hypothesis comes from a positron emission tomography (PET) study demonstrating sex 
differences in glucose metabolism in brain following administration of lorazepam (Wang et al., 1998). 
In that study, bodyweight-adjusted, intravenous administration of lorazepam (30μg/kg) led to similar 
reductions in overall brain metabolic activity in both females and males. However, a sex effect was 
observed in cerebellum, where lorazepam-induced reductions tended to be more pronounced in 
females (-5.9 ±6%) than in males (-1.1 ±6.6%) (Wang et al., 1998). Whilst Wang et al. (1998) did not 
  Manuscript and Figures 
18 
 
observe sex-dependent lorazepam effects on motor or cognitive tasks, we agree with their 
conclusion that “more specific cerebellar tests may have been able to disclose differences between 
the genders in sensitivity to lorazepam’s motor effects” (p. 43) given that we succeeded in showing 
such effects on saccadic spatial accuracy in our study. It should be noted that men also have larger 
cerebellar volume than females, even when adjusted for whole-brain volume (Giedd et al., 2012), 
suggesting they may need a higher dosage to achieve the same occupancy. Interestingly, 
male>female differences in volume are particularly pronounced in motor-related cerebellar areas 
such as lobule VIIIB (Steele and Chakravarty, 2017), an area whose volume we have previously found 
to be related to saccadic spatial accuracy in healthy humans (Ettinger et al., 2005). 
 
These findings of sex-dependent lorazepam effects suggest that anxiolytic treatment effects may 
generally differ by sex, an issue that has previously been raised (Bekker and van Mens-Verhulst, 
2007; Yonkers et al., 1992). Here, the effects of this anxiolytic drug were not observed on a measure 
of anxiety, of course, but on an oculomotor measure. Two issues should be raised in this context. 
First, it is unclear whether sex-dependent drug effects on this measure translate to sex differences in 
the anxiolytic response in patients with anxiety disorders. Second, it should be noted that males in 
this study showed worse performance on these measures than females, suggesting that the observed 
Drug by Sex interaction may reflect a difference in baseline performance, perhaps compatible with 
sex differences in cerebellar metabolism in the absence of pharmacological challenges (Volkow et al., 
1997). Thus, further studies are needed to investigate whether genuine sex differences in drug 
response are observed, even in the absence of baseline performance differences. 
 
Limitations 
The following limitations should be noted. First, we did not measure lorazepam concentrations. 
These may have been helpful in further characterising pharmacodynamics effects, especially as they 
may be affected by age or sex. A second limitation is that we did not obtain weight measures of our 
participants; therefore, it is not possible to relate inter-individual differences in the magnitude of 
drug effects to body weight. 
 
Conclusions and Implications 
To conclude, we confirm that lorazepam dose-dependently reduces saccadic peak velocity. This 
effect is both robust, not being related to various baseline variables, and sensitive, given that effects 
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on peak velocity were greater than those on average velocity. An important additional conclusion 
from this study is that lorazepam effects on saccades are pronounced, leading to deteriorations in 
most measures of saccadic performance investigated here. An implication of this pattern of findings 
is that studies aiming to detect (adverse) effects of benzodiazepine compounds should include 
saccadic parameters other than just the peak velocity in order to obtain a full picture of the drug’s 
effects. Additionally, task factors interacted with lorazepam effects, suggesting that the drug exerts 
negative influences especially at smaller-amplitude saccades. An implication of this finding is that 
future studies should include multiple target positions in order to optimally probe for benzodiazepine 
effects. Finally, a noteworthy finding was that effects of lorazepam on measures of spatial 
consistency were more pronounced for females than males. Whilst this finding of course needs to be 
replicated, it underscores the importance of including both male and female participants in 
pharmacological studies. 
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Figure 1: Effects of Lorazepam on Spatial Accuracy Measures in Males and Females 
 
 
 
Legend: The diagram shows the effects of lorazepam, sex (male, female) and their interaction on (A) variability of amplitude gain and (B) mean spatial error. 
Data are means, error bars reflect ±1 standard error. For illustration purposes, untransformed data are shown but statistical analyses were performed on 
transformed data (see main text). ICV: intra-individual coefficient of variation. N=18 males, N=16 females. # indicates statistical significance following 
Bonferroni correction and n.s. indicates not significant (see main text for details). 
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Figure 2: Effects of Lorazepam on Peak Velocity as a Function of Stimulus Position 
 
 
 
Legend: The diagram shows the effects of lorazepam and stimulus position (near (7.25°), far (14.5°)) as well as their interaction on saccadic peak velocity (in 
degrees per second). Data are means, error bars reflect ±1 standard error. N=34. # indicates statistical significance following Bonferroni correction and n.s. 
indicates not significant (see main text for details). 
